FilingReader Intelligence
Concord Biotech reports stable Q3, eyes long-term 25% growth
February 21, 2025 at 07:06 PM UTC•By FilingReader AI
Concord Biotech (BSE: CONCORDBIO) announced stable Q3 FY25 results with revenue from operations at INR 244 crore, a 1% increase year-over-year. While API revenue saw muted growth, formulation revenue jumped 42% for the nine-month period. EBITDA stood at INR 98 crore with margins at 40.1%. The company's profit after tax was INR 76 crore, a margin of 31.1%.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:CONCORDBIO•Bombay Stock Exchange
News Alerts
Get instant email alerts when Concord Biotech publishes news
Free account required • Unsubscribe anytime